10.1007/s40204-022-00198-3

Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis

  • Cristina Quispe1,
  • Jesús Herrera-Bravo2,
  • Khushbukhat Khan3,
  • Zeeshan Javed4,
  • Prabhakar Semwal5,
  • Sakshi Painuli6,
  • Senem Kamiloglu7,
  • Miquel Martorell8,
  • Daniela Calina9,
  • Javad Sharifi-Rad*10,
  1. Facultad de Ciencias de La Salud, Universidad Arturo Prat, Iquique, 1110939, CL
  2. Departamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Bogotá, CL Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco, 4811230, CL
  3. Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Sector H-12, Islamabad, 44000, PK
  4. Center for Applied Molecular Biology, University of the Punjab, Lahore, PK
  5. Department of Biotechnology, Graphic Era University, Dehradun, IN Uttarakhand State Council for Science and Technology, Dehradun, IN
  6. Department of Biotechnology, Graphic Era University, Dehradun, IN
  7. Science and Technology Application and Research Center (BITUAM), Bursa Uludag University, Gorukle, Bursa, 16059, TR
  8. Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepción, Concepción, 4070386, CL
  9. Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, 200349, RO
  10. Facultad de Medicina, Universidad del Azuay, Cuenca, EC

Published in Issue 2022-07-29

How to Cite

Quispe, C., Herrera-Bravo, J., Khan, K., Javed, Z., Semwal, P., Painuli, S., Kamiloglu, S., Martorell, M., Calina, D., & Sharifi-Rad, J. (2022). Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis. Progress in Biomaterials, 11(4 (December 2022). https://doi.org/10.1007/s40204-022-00198-3
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Abstract Medicinal applications of turmeric-derived curcumin have been known to mankind for long ages. Its potential in managing “cystic fibrosis” has also been evaluated. This autosomal recessive genetic disease is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) which involves an impaired secretion of chloride ions and leads to hypersecretion of thick and sticky mucus and serious complications including airway obstruction, chronic lung infection, and inflammatory reactions. This narrative review aims to highlight the available evidence for the efficacy of curcumin nanoformulations in its potential treatment of cystic fibrosis. Recent research has shown that curcumin acts on the localized mutant CFTR ion channel at the plasma membrane. Preclinical studies have also shown that curcumin nanoformulations have promising effects in the treatment of cystic fibrosis. In this context, the purpose of this narrative review is to highlight the general bioactivity of curcumin, the types of formulations and related studies, thus opening new therapeutic perspectives for CF.

Keywords

  • Cystic fibrosis,
  • Curcumin nanoparticles,
  • Bioavailability,
  • Molecular mechanisms,
  • Signalling pathways

References

  1. Adel et al. (2021) Design and characterization of spray-dried proliposomes for the pulmonary delivery of curcumin (pp. 2667-2687) https://doi.org/10.2147/IJN.S306831
  2. Akaberi et al. (2021) Turmeric and curcumin: from traditional to modern medicine (pp. 15-39) https://doi.org/10.1007/978-3-030-56153-6_2
  3. Alexa et al. (2020) A comprehensive behavioural assessment of curcumin's effect on inflammatory and non-inflammatory pain in mice (pp. 829-834) https://doi.org/10.31925/farmacia.2020.5.8
  4. Ayubi et al. (2019) Magnetic nanoparticles decorated with PEGylated curcumin as dual targeted drug delivery: synthesis, toxicity and biocompatibility study https://doi.org/10.1016/j.msec.2019.109810
  5. Bengtson et al. (2021) Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance 57(1)
  6. Berger et al. (2005) Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl- channel activity (pp. 5221-5226) https://doi.org/10.1074/jbc.M412972200
  7. Cartiera et al. (2010) Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin (pp. 86-93) https://doi.org/10.1021/mp900138a
  8. Chaudhary et al. (2019) Curcumin down-regulates toll-like receptor-2 gene expression and function in human cystic fibrosis bronchial epithelial cells (pp. 489-495) https://doi.org/10.1248/bpb.b18-00928
  9. Chiu et al. (2019) Cystic fibrosis transmembrane conductance regulator: a possible new target for photodynamic therapy enhances wound healing (pp. 476-486) https://doi.org/10.1089/wound.2018.0927
  10. Cristallini et al. (2019) Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier (pp. 19-28) https://doi.org/10.1016/j.msec.2018.10.064
  11. Cystic Fibrosis Foundation (2020) About Cystic Fibrosis. Retrieved from:
  12. https://www.cff.org
  13. Docea et al. (2020) The effect of silver nanoparticles on antioxidant/pro-oxidant balance in a murine model https://doi.org/10.3390/ijms21041233
  14. Dragomir et al. (2004) Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells (pp. 447-451) https://doi.org/10.1016/j.bbrc.2004.07.146
  15. Egan et al. (2004) Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects (pp. 600-602) https://doi.org/10.1126/science.1093941
  16. El-Sherbiny and Smyth (2012) Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles (pp. 269-280) https://doi.org/10.1021/mp200351y
  17. Flora et al. (2013) Nanocurcumin: a promising therapeutic advancement over native curcumin (pp. 331-368) https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2013007236
  18. Goncalves et al. (2017) Curcumin/poly(2-methyl-2-oxazoline-b-tetrahydrofuran-b-2-methyl-2-oxazoline) formulation: An improved penetration and biological effect of curcumin in F508del-CFTR cell lines (pp. 168-181) https://doi.org/10.1016/j.ejpb.2017.04.015
  19. Guichard et al. (2017) Production and characterization of a PEGylated derivative of recombinant human deoxyribonuclease I for cystic fibrosis therapy (pp. 159-167) https://doi.org/10.1016/j.ijpharm.2017.03.057
  20. Guichard et al. (2018) Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum (pp. 1439-1452) https://doi.org/10.1042/CS20180315
  21. Guichard et al. (2021) PEGylation of recombinant human deoxyribonuclease I provides a long-acting version of the mucolytic for patients with cystic fibrosis https://doi.org/10.1002/adtp.202000146
  22. Guo et al. (2020) Effects of curcumin on inhibiting the proliferation of pulmonary artery smooth muscle cells and relieving pulmonary arterial hypertension (pp. 307-312) https://doi.org/10.31925/farmacia.2020.2.16
  23. Harada et al. (2007) Curcumin enhances cystic fibrosis transmembrane regulator expression by down-regulating calreticulin (pp. 351-356) https://doi.org/10.1016/j.bbrc.2006.12.036
  24. Jacob et al. (2018) Types I and II keratin intermediate filaments 10(4) https://doi.org/10.1101/cshperspect.a018275
  25. Jennings et al. (2021) Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies https://doi.org/10.1016/j.celrep.2021.108782
  26. Kalaycioglu et al. (2017) Antimicrobial and physical properties of chitosan films incorporated with turmeric extract (pp. 882-888) https://doi.org/10.1016/j.ijbiomac.2017.03.174
  27. Kelly and Buxbaum (2015) Gastrointestinal manifestations of cystic fibrosis (pp. 1903-1913) https://doi.org/10.1007/s10620-015-3546-7
  28. Kocaadam and Sanlier (2017) Curcumin, an active component of turmeric (Curcuma longa), and its effects on health (pp. 2889-2895) https://doi.org/10.1080/10408398.2015.1077195
  29. Kuang et al. (2020) Curcumin-loaded PEGylated mesoporous silica nanoparticles for effective photodynamic therapy (pp. 24624-24630) https://doi.org/10.1039/D0RA04778C
  30. Lababidi et al. (2019) Microfluidics as tool to prepare size-tunable PLGA nanoparticles with high curcumin encapsulation for efficient mucus penetration (pp. 2280-2293) https://doi.org/10.3762/bjnano.10.220
  31. Lababidi et al. (2020) Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles (pp. 200-210) https://doi.org/10.1016/j.ejpb.2020.10.010
  32. Lampe and Milobedeska (1913) Studien über curcumin (pp. 2235-2240)
  33. Li et al. (2020) Curcumin, the golden spice in treating cardiovascular diseases https://doi.org/10.1016/j.biotechadv.2019.01.010
  34. Li et al. (2021) Highlighting membrane protein structure and function: a celebration of the protein data bank https://doi.org/10.1016/j.jbc.2021.100557
  35. Lin et al. (2018) PEGylated lipid bilayer coated mesoporous silica nanoparticles for co-delivery of paclitaxel and curcumin: Design, characterization and its cytotoxic effect (pp. 272-282) https://doi.org/10.1016/j.ijpharm.2017.10.043
  36. Lipecka et al. (2006) Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network (pp. 500-505) https://doi.org/10.1124/jpet.105.097667
  37. Lukacs and Verkman (2012) CFTR: folding, misfolding and correcting the DeltaF508 conformational defect (pp. 81-91) https://doi.org/10.1016/j.molmed.2011.10.003
  38. Mahmmoud (2005) Curcumin modulation of Na, K-ATPase: phosphoenzyme accumulation, decreased K+ occlusion, and inhibition of hydrolytic activity (pp. 236-245) https://doi.org/10.1038/sj.bjp.0706185
  39. Ma'mani et al. (2014) Curcumin-loaded guanidine functionalized PEGylated I3ad mesoporous silica nanoparticles KIT-6: practical strategy for the breast cancer therapy (pp. 646-654) https://doi.org/10.1016/j.ejmech.2014.06.069
  40. Matei et al. (2021) Applications of nanosized-lipid-based drug delivery systems in wound care https://doi.org/10.3390/app11114915
  41. Milobedeska et al. (1910) Structure of curcumin (pp. 2163-2170)
  42. Muralidharan et al. (2014) Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers (pp. 333-353) https://doi.org/10.3390/pharmaceutics6020333
  43. Nelson et al. (2017) The essential medicinal chemistry of curcumin: miniperspective (pp. 1620-1637) https://doi.org/10.1021/acs.jmedchem.6b00975
  44. Oliver et al. (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection (pp. 1251-1254) https://doi.org/10.1126/science.288.5469.1251
  45. Ong et al. (2019) Nanomedicine for cystic fibrosis (pp. 169-180) https://doi.org/10.1177/2472630318824334
  46. Pandey et al. (2011) Design, synthesis and evaluation of novel PEGylated curcumin analogs as potent Nrf2 activators in human bronchial epithelial cells (pp. 16-24) https://doi.org/10.1016/j.ejps.2011.03.003
  47. Pinzaru et al. (2018) Stable PEG-coated silver nanoparticles - A comprehensive toxicological profile (pp. 546-556) https://doi.org/10.1016/j.fct.2017.11.051
  48. Prasad et al. (2014) Curcumin, a component of golden spice: from bedside to bench and back (pp. 1053-1064) https://doi.org/10.1016/j.biotechadv.2014.04.004
  49. Quispe et al. (2022) Therapeutic applications of curcumin in diabetes: a review and perspective https://doi.org/10.1155/2022/1375892
  50. Rafeey et al. (2020) Effects of curcumin supplementation on quality of life of cystic fibrosis patients (pp. 11169-11176)
  51. Roointan et al. (2016) A comparison between PLGA-PEG and NIPAAm-MAA nanocarriers in curcumin delivery for hTERT silencing in lung cancer cell line (pp. 51-56)
  52. Rubin (2007) Mucus structure and properties in cystic fibrosis (pp. 4-7) https://doi.org/10.1016/j.prrv.2007.02.004
  53. Rupel et al. (2021) Antimicrobial activity of amphiphilic nanomicelles loaded with curcumin against Pseudomonas aeruginosa alone and activated by blue laser light https://doi.org/10.1002/jbio.202000350
  54. Saint-Criq and Gray (2017) Role of CFTR in epithelial physiology (pp. 93-115) https://doi.org/10.1007/s00018-016-2391-y
  55. Sala et al. (2021) Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives https://doi.org/10.1016/j.ejmech.2021.113191
  56. Salehi et al. (2020) Curcumin's nanomedicine formulations for therapeutic application in neurological diseases
  57. Sharifian et al. (2020) Investigating the effect of nano-curcumin on the expression of biofilm regulatory genes of pseudomonas aeruginosa (pp. 2477-2484) https://doi.org/10.2147/IDR.S263387
  58. Song et al. (2004) Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models (pp. 40629-40633) https://doi.org/10.1074/jbc.M407308200
  59. Stephenson et al. (2017) The changing epidemiology and demography of cystic fibrosis (pp. e87-e95) https://doi.org/10.1016/j.lpm.2017.04.012
  60. Sun et al. (2012) Advances in nanotechnology-based delivery systems for curcumin (pp. 1085-1100) https://doi.org/10.2217/nnm.12.80
  61. Taheri et al. (2021) The burden of the serious and difficult-to-treat infections and a new antibiotic available: cefiderocol https://doi.org/10.3389/fphar.2020.578823
  62. Talebi et al. (2021) The effects of nano-curcumin as a nutritional strategy on clinical and inflammatory factors in children with cystic fibrosis: the study protocol for a randomized controlled trial (pp. 1-11) https://doi.org/10.1186/s13063-021-05224-6
  63. Talwalkar and Murray (2016) The approach to pseudomonas aeruginosa in cystic fibrosis (pp. 69-81) https://doi.org/10.1016/j.ccm.2015.10.004
  64. Trandafir et al. (2019) Current practices and potential nanotechnology perspectives for pain related to cystic fibrosis https://doi.org/10.3390/jcm8071023
  65. Tsoukalas et al. (2019) Metabolic fingerprint of chronic obstructive lung diseases: a new diagnostic perspective https://doi.org/10.3390/metabo9120290
  66. Velino et al. (2019) Nanomedicine approaches for the pulmonary treatment of cystic fibrosis https://doi.org/10.3389/fbioe.2019.00406
  67. Villamizar et al. (2019) Targeted activation of cystic fibrosis transmembrane conductance regulator (pp. 1737-1748) https://doi.org/10.1016/j.ymthe.2019.07.002
  68. Vogel (1842) Die Bibliothek Der Benediktinerabtei Sponheim (pp. 312-328)
  69. Vogel HA, Pelletier J (1815)
  70. Curcumin–biological and medicinal properties. J Pharma 2:50
  71. Wang (2015) Interplay between inhibitory ferric and stimulatory curcumin regulates phosphorylation-dependent human cystic fibrosis transmembrane conductance regulator and DeltaF508 activity (pp. 1558-1566) https://doi.org/10.1021/bi501318h
  72. Wang et al. (2007) Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains (pp. 4533-4544) https://doi.org/10.1074/jbc.M609942200
  73. Yallapu et al. (2013) Curcumin nanomedicine: a road to cancer therapeutics (pp. 1994-2010)
  74. Yallapu et al. (2015) Therapeutic applications of curcumin nanoformulations (pp. 1341-1356) https://doi.org/10.1208/s12248-015-9811-z
  75. Yavarpour-Bali et al. (2019) Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders (pp. 4449-4460) https://doi.org/10.2147/IJN.S208332
  76. Zeitlin (2004) Can curcumin cure cystic fibrosis? (pp. 606-608) https://doi.org/10.1056/NEJMcibr041584